Intra-Cellular Therapies (ITCI) signed a definitive agreement with pharma bigwig Johnson & Johnson (JNJ) . Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash, aggregating to nearly $14.6 billion.A commercial-stage biotech company, Intra-Cellular is focused on developing and marketing novel drugs targeting neuropsychiatric and neurological disorders.The acquisition will add ITCI’s sole marketed drug, Caplyta, which is approved for two indications — schizoph ...